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Abstract
The predominant X-linked form of Dyskeratosis congenita results from mutations in DKC1, which encodes dyskerin, a
protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously
found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis
congenita (X-DC) patient cells. Here we have found that an increased basal and induced DNA damage response occurred in
X-DC cells in comparison with normal cells. DNA damage that is also localized in telomeres results in increased
heterochromatin formation and senescence. Expression of a cDNA coding for GSE24.2 rescues both global and telomeric
DNA damage. Furthermore, transfection of bacterial purified or a chemically synthesized GSE24.2 peptide is able to rescue
basal DNA damage in X-DC cells. We have also observed an increase in oxidative stress in X-DC cells and expression of
GSE24.2 was able to diminish it. Altogether our data indicated that supplying GSE24.2, either from a cDNA vector or as a
peptide reduces the pathogenic effects of Dkc1 mutations and suggests a novel therapeutic approach.
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Introduction
Telomeres are nucleoprotein complexes located at the ends of
linear chromosomes and consist of tandem repeats of simple DNA
sequences (TTAGGG in humans) and proteins that interact
directly or indirectly with these sequences [1]. Sequence erosion of
terminal repeats is inherent to each round of genome replication.
The replenishment of the telomeric repeats is accomplished by the
extension of their 39 ends, through a reaction mediated by the
telomerase complex [2]. In humans, the active telomerase complex
consists of a minimum of three essential components: hTERT,
hTR and dyskerin [3]. Besides forming part of the telomerase
complex, dyskerin is a pseudouridine synthase component of H/
ACA small nuclear RNPs [4], complexes that mediate the
conversion of specific uridines (U) to pseudouridine in newly
synthesized ribosomal RNAs [5] [6] [7]. Point mutations in
dyskerin cause a rare disease named X-linked dyskeratosis
congenita (X-DC) [8]. Individuals with X-DC display features of
premature ageing, as well as nail dystrophy, mucosal leukoplakia,
interstitial fibrosis of the lung and increased susceptibility to cancer
[9]. The tissues affected by X-DC, such as bone marrow and skin,
are characterized by the high rate of turnover of their progenitor
cells.
Telomere shortening prevents the formation of the loop-like
structure maintained by a nucleoprotein structure consisting of
telomeric DNA and 6 proteins that are together known as shelterin
[1]. This capping structure prevents the otherwise exposed ends of
different chromosomes from being recognized as double strand
breaks (DSBs) by the cell’s DNA repair machinery which would
result in telomere fusion. When telomeres become critically short
or unprotected because of shelterin deficiency, they trigger a DNA
damage response (DDR), leading to the activation of an ataxia
telangiectasia mutated (ATM) or ataxia telangiectasia and Rad3
related (ATR)-dependent DNA damage response at chromosome
ends [10] [11] [12] [13]. 53BP1 is a C-non-homologous-end-
joining (C-NHEJ) component and an ATM target that accumu-
lates at DSBs and uncapped telomeres [14] [15]. The binding of
53BP1 close to DNA breaks impacts the dynamic behavior of the
local chromatin and facilitates the non-homologous-end-joining
(NHEJ) repair reactions that involve distant sites [16]. ATM
phosphorylates Chk2 leading to activation of cell cycle check-
points. Chk2 acts as a signal distributor, dispersing checkpoint
signal to downstream targets such as p53, Cdc25A, Cdc25C,
BRCA1 and E2F1 [17].
Senescence, initially described as stable cell proliferation arrest,
can be induced by telomere shortening and also by activated
oncogenes, DNA damage and drug-like inhibitors of specific
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enzymatic activities [18]. Senescent cells are typically character-
ized by a large flat morphology and the expression of a senescence-
associated-b-galactosidase (SA-b-gal) activity of unknown function.
In the nucleus of senescent cells chromatin undergoes dramatic
remodeling through the formation of domains of heterochromatin
called senescence-associated heterochromatin-foci (SAHF). SAHF
contain histone modifications and proteins characteristic of silent
heterochromatin such as methylated lysine 9 of histone H3
(H3K9me), heterochromatin protein 1 (HP1), and the histone
H2A variant macroH2A.1 [18] [19]. Proliferation-promoting
genes such as E2F-target genes (e.g. cyclin A) are recruited into
SAHF, dependent on the pRB suppressor protein, thereby
irreversibly silencing expression of those genes.
In cultured cells and animal models, telomere erosion promotes
chromosomal instability via breakage-fusion-bridge cycles, con-
tributing to the early stages of tumorigenesis. Telomere shortening
in Dyskeratosis congenita is associated with a higher risk of some
types of cancer such as head and neck squamous cell carcinoma
(HNSCC) (mostly tongue), skin squamous cell carcinoma (SCC),
anogenital, stomach, esophagus, and lymphomas, as well as
myelodysplastic syndrome (MDS) [20] [21] [22] [23]. Altogether,
these findings provide direct clinical evidence that short telomeres
in hematopoietic cells are dysfunctional, mediate chromosomal
instability and predispose to malignant transformation in a human
disease.
We previously isolated the peptide GSE24.2, in a screen of
cDNAs for those that confer survival ability on cells treated with
cisplatin [24]. Intriguingly GSE24.2 turned out to be a short
dyskerin fragment containing two highly conserved motifs
implicated in pseudouridine synthase catalytic activity. GSE24.2
prevents telomerase inhibition mediated by different chemother-
apeutic agents, including cisplatin and telomerase inhibitors. In X-
DC cells and WI-38-VA13 cells, GSE24.2 induces an increase in
hTERT mRNA levels and the recovery of telomerase activity [24].
Mutations in DKC1 lead to severe destabilization of telomerase
RNA (TR), a reduction in telomerase activity and a significant
continuous loss of telomere length during growth [25]. When a
peptide encoding GSE24.2, was introduced into mutant cells, it
rescued telomerase activity and prevented the decrease in TR
levels induced by the Dkc1 mutation [26] GSE24.2 was recently
approved as an orphan drug for the treatment of Dyskeratosis
congenita (EU/3/12/1070 - EMA/OD/136/11).
To obtain more information on the biological activity of this
dyskerin fragment we studied its effect on the DNA damage
pathway in patient derived X-DC cells and a mouse F9 cell line
carrying the A353V mutation in the Dkc1 gene [26]. This is the
mutation most frequently found in patients with X-DC (about
40% of patients) [27] [28] and is localized in the PUA RNA
binding domain, the putative site for interaction with hTR.
Recently, it has been described that mouse ES cells expressing a
small dyskerin deletion, removing exon 15 of Dkc1, additionally
showed decreased proliferative rate and increased sensitivity to
DNA damage [29] that was independent on telomere length
suggesting that decreased telomerase activity induced by the
mutation in Dkc1 resulted in induction of DNA damage probably
by extratelomeric activity of Dkc1 gene. Therefore the use of a
mouse F9A353V model would allow study the effect of GSE24.2
directly on DNA damage, independently of telomeric elongation.
Here we show that human X-DC cells showed both basal DNA
damage foci and phosphorylation of ATM and CHK2 together
with increased content of heterochromatin. Expression of the
GSE24.2 was able to reduce DNA damage in X-DC patient and
F9 X-DC mouse cell line models, by decreasing the formation of
DNA damage foci. Finally, we also report that expression of
GSE24.2 decreases oxidative stress in X-DC patient cells and that
may result in reduced DNA damage. These data support the
contention that expression of GSE24.2, or related products, could
prolong the lifespan of dyskeratosis congenita cells.
Materials and Methods
Cell lines and constructs
Dermal fibroblasts from a control proband (X-DC-1787-C) and
two X-DC patients (X-DC-1774-P and X-DC3) were obtained
from Coriell Cell Repository. GSE24.2, DKC, motif I and motif II
were cloned as previously described in the pLXCN vector [24].
PGATEV protein expression plasmid [30] was obtained from Dr.
G. Montoya. PGATEV-GSE24.2 was obtained by subcloning the
GSE24.2 fragment into the NdeI/XhoI sites of the pGATEV
plasmid as previously described [24].
F9 cells and F9 cells transfected with A353V targeting vector
were previously described [31] [26]. F9A353V cells were cultured
in Dulbecco modified Eagle medium (DMEM) 10% fetal bovine
serum, 2 mM glutamine (Gibco) and Sodium bicarbonate (1,5 gr/
ml).
Cell transfection and analysis of gene expression
F9 cells were transfected with 16 mg of DNA/106 cells, using
lipofectamine plus (Invitrogen, Carlsbad, USA), according to the
manufacturer’s instructions. Peptides transfection was performed
by using the Transport Protein Delivery Reagent (50568; Lonza,
Walkersville, USA) transfection kit. Routinely from 6 to 15 mg
were used per 30 mm dish.
Antibodies. The source of antibodies was as follow: phospho-
Histone H2A.X Ser139 (2577; Cell Signaling), phospho-Histone
H2A.X Ser139 clone JBW301 (05-636; Millipore), macroH2A.1
(ab37264; abcam), 53BP1 (4937; Cell Signaling), anti-ATM
Protein Kinase S1981P (200-301-400; Rockland), phospho-
Chk2-Thr68 (2661; Cell Signaling), Monoclonal Anti-a-tubulin
(T9026; Sigma-Aldrich), Anti-8-Oxoguanine Antibody, clone
483.15 (MAB3560, Merck-Millipore). Fluorescent antibodies were
conjugated with Alexa fluor 488 (A11029 and A11034, Molecular
Probes) and Alexa fluor 647 (A21236, Molecular Probes,
Carlsbad, USA)).
Immunofluorescence and Fluorescence in situ
hybridization (FISH) for telomeres
Protein localization was carried out by fluorescence microscopy.
For this purpose, cells were grown on coverslips, transfected and
fixed in 3.7% formaldehyde solution (47608; Fluka, Sigma, St.
Louis, USA) at room temperature for 15 min. After washing with
1x PBS, cells were permeabilized with 0.2% Triton X-100 in PBS
and blocked with 10% horse serum before overnight incubation
with c-H2A.X, 53BP1, p-ATM, p-CHK2 antibodies. Finally, cells
were washed and incubated with secondary antibodies coupled to
fluorescent dyes (alexa fluor 488 or/and alexa fluor 647).
For immuno-FISH, immunostaining of 53BP1 was performed
as described above and followed by incubation in PBS 0,1%
Triton X-100, fixation 5 min in 2% paraformaldehyde (PFA),
dehydration with ethanol and air-dried. Cells were hybridized with
the telomeric PNA-Cy3 probe (PNA Bio) using standard PNA-
FISH procedures. Imaging was carried out at room temperature in
Vectashield, mounting medium for fluorescence (Vector Labora-
tories, Burlingame, USA). Images were acquired with a Confocal
Spectral Leica TCS SP5. Using a HCX PL APO Lambda blue
6361.40 OIL UV, zoom 2.3 lens. Images were acquired using
LAS-AF 1.8.1 Leica software and processed using LAS-AF 1.8.1
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Leica software and Adobe Photoshop CS. Colocalization of 53BP1
foci and the PNA FISH probe was quantified in at least 200 cells.
Telomeric repeat amplification protocol (TRAP) assay
Telomerase activity was measured using the TRAPeze kit [32]
(Millipore, Billerica, MA USA) according to the manufacturer’s
recommendations. TRAP assay activity was normalized with the
internal control [24].
Real-time quantitative PCR
RNA isolation and cDNA synthesis. Total cellular RNA
was extracted using Trizol (Invitrogen, Carlsbad, USA) according
to the manufacturer’s instructions. For reverse transcription
reactions (RT), 1 mg of the purified RNA was reverse transcribed
using random hexamers with the High-Capacity cDNA Archive
kit (Applied Biosystems, P/N: 4322171; Foster City, CA)
according to the manufacturer’s instructions. RT conditions
comprised an initial incubation step at 25uC for 10 min. to allow
random hexamers annealing, followed by cDNA synthesis at 37uC
for 120 min, and a final inactivation step for 5 min. at 95uC.
Measurement of mRNA Levels. The mRNA levels were
determined by quantitative real-time PCR analysis using an ABI
Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA). Gene-specific primer pairs and probes for SOD1
(SOD Cu/Zn), SOD2 (SOD Mn), GPX1 (Glutathione peroxidase 1) and
CAT (Catalase) (Assay-on-demand, Applied Biosystems), were used
together with TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, USA) and 2 ml of reverse transcribed
sample RNA in 20 ml reaction volumes. PCR conditions were
10 min. at 95uC for enzyme activation, followed by 40 two-step
cycles (15 sec at 95uC; 1 min at 60uC). The levels of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) expression were mea-
sured in all samples to normalize gene expression for sample-to-
sample differences in RNA input, RNA quality and reverse
transcription efficiency. Each sample was analyzed in triplicate,
and the expression was calculated according to the 22DDCt
method.
GSE24.2 peptide production and purification
E. Coli DH5a cells were transformed with pGATEV GSE24.2
and lysates prepared as described [30]. The fusion protein was
purified with glutathione-sepharose and purity analyzed by gel
electrophoresis. GSE24.2 was obtained from the purified fusion
protein by TEV protease digestion according to the manufactur-
er’s recommendations. Typically, over 90% of the fusion protein
was cleaved, as determined by SDS-PAGE. The protein was
passed twice over a 5 ml Hi-Trap Ni-NTA column to remove the
polyhistidine tags, un-cleaved protein, TEV protease and impu-
rities. Synthetic GSE24.2 was obtained from Peptide 2.0 Inc
(Chantilly, USA) and purified by HPLC
Western Blot
Whole-cell extracts were prepared essentially as described
previously [33]. Nuclear extracts were obtained as previously
reported [24]. Western blotting was performed using standard
methods [33]. Protein concentration was measured by using the
Bio-Rad protein assay.
Senescence analysis
Control and X-DC fibroblasts (16104 cells) were plated onto 6
well plates and fixed after four days to assay the SA-b-gal
(Senescence Detection Kit, BioVision, Milpitas, USA). The
percentage of senescent cells was calculated in 6 images per
sample taken in the bright field microscopy at 1006magnification
(Nikon Eclipse TS100 Microscopy, Melville, NY, USA).
Determination of reactive oxygen species (ROS) content
with dihydroethidium
Cells were cultured in 12 chamber plates for 4 days (at
confluence). Afterwards cells were washed 2 times with pre-
warmed PBS medium, 2 mL/mL of diluted dihydroethidium
(Dihydroethidium, D7008-Sigma, St. Louis, USA) was added to
the plate. Cells were incubated at 37uC for 20 min. After washing
the plate with PBS, medium was replaced, and cells cultured for an
additional 1 hour at 37uC. The fluorescence was measured using
spectraMAX GEMINIS (Molecular Device, Sunnyvale, USA),
with 530 nm of excitation wavelength and 610 nm of emission
wavelength. Mean fluorescence intensity (MFI) for each cell line,
was normalized by the cellular protein content.
Measurement of CuZnSOD and MnSOD activity
To determine MnSOD and CuZnSOD activity the cells were
treated as described in the Cayman ‘‘Superoxide Dismutase Assay
kit’’ (Ann Arbor, USA). After centrifugation at 10,000 g for
10 min, supernatant was used to measure CuZnSOD activity. The
mitochondrial pellet was lysed using a lysis buffer compatible with
the manufacturer’s instructions (10 mM HEPES, pH7.9, 420 mM
NaCl, 1,5 mM MgCl2, 0,5 mM EDTA, 0.1% Triton X-100) for
20 min on ice. After centrifugation at 12,000 g for 5 min, the
supernatant was collected for MnSOD activity assay. Measure-
ments of CuZnSOD and MnSOD activities were performed in a
96 well plate prepared using 3–4 replicates from different cellular
extracts for each sample. The final absorbance was measured at
450 nm using a spectrophotometer spectraMAXPLUS 384
(Molecular Devices, Sunnyvale, USA).
Measurement of catalase activity
The method for measuring the catalase enzymatic activity was
based on the reaction of the enzyme with methanol in the presence
of hydrogen peroxide to produce formaldehyde. Cells were lysed
using freeze (liquid N2, 10 s) and thaw (ice, 15 min) procedure
repeated three times. After centrifugation of the cell lysate at
13,000 g, for 10 min. at 4uC, supernatants were recovered and
quantified using Lowry method. A 96 well plate was prepared
using at least 4 replicates for each sample, obtained from different
cellular extracts.
Assay reaction consisted in mixing on a 96 well plate: 100 mL of
phosphate buffer 100 mM pH 7.0; 30 mL methanol and 20 mL of
the sample with the same protein concentration. Then, the
reaction was started with 20 mL of 85 mM H2O2, maintained
during 20 min at room temperature and finally stopped using
30 mL of KOH 10 M. The formaldehyde produced reacts with
35 mM purpald reagent dissolved in 0,5 M HCl during 10 min at
room temperature. Finally, 10 mL of 0.5% KIO4 in KOH 0.5 M
were added and the absorbance at the wavelength of 540 nm was
measured with spectrophotometer spectra MAXPLUS 384
(Molecular Devices, Sunnyvale, USA).
Measurement of glutathione peroxidase activity
Gpx activity was measured by using a glutathione peroxidase
assay kit (Cayman (Ann Arbor, USA). Briefly, cells were collected
and lysed using cold buffer (50 mM Tris-HCl, pH 7.5, 5 mM
EDTA and 1 mM DTT) and two freeze-thaw cycles as described
above. The lysates were centrifuged at 10,000 g for 15 min at 4uC
and the supernatants recovered in fresh tubes. A 96 well plate was
prepared using at least 3 replicates for each sample from different
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cellular extracts. After protein quantification by Lowry method,
samples containing 20 mg of total proteins were added to the 96
well plate containing a solution with 1 mM GSH, 0.4 U/mL of
glutathione reductase, 0.2 mM NADPH. The reaction was
initiated by adding 0.22 mM of cumene hydroperoxide and the
reduction of the absorbance was recorded at 340 nm each 1 min
during 8 min. The Gpx activity was determined by the rate of
decrease in absorbance at 340 nm (1 mU/mL Gpx). Molar
coefficient extinction for NADPH was 0.00622 mM21 cm21.
Statistical analysis
For the statistical analysis of the results, the mean was taken as
the measurement of the main tendency, while standard deviation
was taken as the dispersion measurement. T-Student was
performed. The significance has been considered at *p,0.05, **
Figure 1. DNA damage signaling in X-DC patient cells. (A) Immunofluorescence staining of DNA damage proteins. Control X-DC-1787-C and
patient X-DC-1774-P cells were, either not treated (-Bleo) or treated (+Bleo) with bleomycin (10 mg/ml) for 24 hours, fixed and incubated with
antibodies against c-H2AX, 53BP1, p-ATM or p-CHK1 and secondary fluorescent antibodies. Nuclear DNA was counterstained with DAPI (blue). (B).
Quantification of c-H2A.X foci, pATM, 53BP1 and pCHK2 associated foci in X-DC-1787-C and X-DC-1774-P cells. More than 200 cells were analyzed in
each cell line and indicated as the average number of foci/cell. Asterisks indicate significant differences in relation to control cells lines or to untreated
cells. Average values and standard deviations of two independent experiments are shown. Experiments were repeated 3 times with similar results.
doi:10.1371/journal.pone.0101424.g001
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for p,0.01 and *** for p,0.001. GraphPad Software v5.0 was
used for statistical analysis and graphic representations.
Results
1-Basal and induced DNA damage response in X-DC cells
involves 53BP1, ATM and CHK2 and results in increased
heterochromatin formation and senescence
It has been previously demonstrated [29] that a pathogenic
mutation in murine Dkc1 causes growth impairment and the
enhancement of DNA damage responses after treatment with the
chemotherapeutic agent etoposide. In the context of telomeres of
normal length, cells with the dyskerin mutation Dkc1D15 (deletion
of exon 15) showed increased number of DNA damage foci as
observed by detection of p-H2A.XSer139 (c-H2A.X) foci and
activation of the ATM/p53 pathway.
We have used paired human cell lines (heterozygous carrier and
patient) harboring the same mutation in DKC gene, responsible for
X-DC and studied the DNA damage response pathway. Telomere
length of the control cell line (healthy carrier grandmother from
X-DC-1774-P patient) was the right length for the age of this
control (60 year old and 10.7 kpb). Both basal DNA damage and
that produced in response to the DNA damaging agent bleomycin
were studied. Our results show that the number of c-H2A.X-
associated foci/cell was dramatically higher in cells obtained from
the X-DC-1774-P patient than in the carrier cell line X-DC-1787-
C (Fig. 1A and B). When cells were treated with bleomycin, which
induces double strand breaks, we found an increase in the number
of c-H2A.X associated foci/cell in both X-DC-1774-P and X-DC-
1787-C cells. Although basal DNA damage in X-DC-1774-P was
already much higher than that of control cells the increase was
similar or even lower to that observed in control cells. We also
investigated the presence of 53BP1 foci in these cell lines, since
53BP1 is recruited to DNA-damage associated foci. We found the
average number of foci/cell was similar to that observed for c-
H2A.X, higher to that observed in control cells but even if there is
an increase after bleomycin treatment, the increase in the number
of foci/cell was smaller than control cells ATM protein is also
recruited to DNA-damage sites at the chromatin and phosphor-
ylated, we found that X-DC-1774-P cells showed higher number
of foci/cell with phosphorylated ATM compared to carrier cells.
In bleomycin treated cells both patient and carrier cells showed
increased response to DNA damage although similar to what
happen with the other indicators of DNA damage the increase
observed in X-DC-1774-P was lower than control cells. CHK2 is a
protein, substrate of ATM-kinase. We studied the number of cells
with phosphorylated CHK2 at Thr68 and found a higher number
of foci/cells in X-DC-1774-P in untreated cells, which increases
after bleomycin treatment, but such increase is lower than control
cells. Altogether these results indicate that basal DNA damage is
higher in X-DC patient cells that in mutation carrier cells, in
response to bleomycin this increase is not higher in X-DC cells
probably due to the high basal damage observed in these cells.
Furthermore we have found that the signaling pathway associated
with this DNA damage, include at least 53BP1, ATM and CHK2,
although we cannot exclude the participation of other proteins.
In order to verify if X-DC cells harbor an increased
heterochromatin content we studied the nuclear distribution of
histone-macroH2A.1-associated heterochromatin in X-DC-1774-
P and X-DC-1787-C cells, both in basal conditions and after
bleomycin treatment (Fig. 2A). X-DC-1774-P cells already showed
an average of 20% of the nuclear area with positive expression for
macroH2A.1, and after bleomycin treatment we detected an
increase up to 30% (Fig. 2B). X-DC-1787-C cells showed a very
Figure 2. Determination of Histone-macroH2A.1-associated
heterochromatin and senescence in X-DC cells. (A) Histone-
macroH2A.1-associated heterochromatin detection in X-DC cells. X-DC-
1787-C and X-DC-1774-P cells were either not treated (-Bleo) or treated
(+Bleo) with bleomycin (10 mg/ml) for 24 hours, fixed and incubated
with an antibody against Histone-macroH2A.1 followed by a secondary
fluorescence labeled antibody. (B) Quantification of Histone-
macroH2A.1-associated heterochromatin. More than 200 cells were
analyzed in each cell line and grouped to the area presenting Macro
H2A.1 foci per cell. Asterisks indicate significant differences between
cells lines. Average values and standard deviations of two independent
experiments are shown. (C) SA-b-gal activity in X-DC-1787-C and X-DC-
1774-P cells either untreated (-Bleo) or treated (+Bleo) with bleomycin
(10 mg/ml). Senescent cells were quantified in 6 images of random
regions. Experiments were repeated 3 times with similar results.
Asterisks indicate significant differences in response to bleomycin.
doi:10.1371/journal.pone.0101424.g002
Rescue of DNA Damage with GSE24.2
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e101424
low expression in basal conditions that increases to almost 20%
after bleomycin treatment (Fig. 2C). These data indicated that X-
DC patient cells show extensive areas of heterochromatin that
further increased in response to bleomycin. Thus, both basal and
induced DNA damage may trigger a relevant silencing of gene
expression in these cells. Almost 60% of X-DC-1774-P cells were
Figure 3. Localization of 53BP1 foci to telomeres in X-DC patient cells. X-DC-1787-C and X-DC-1774-P cells untreated (-Bleo) or treated (+
Bleo) with bleomycin (10 mg/ml) and incubated with c-H2A.X and PNA-FISH probe. (A) Colocalization of 53BP1 foci (green) and telomeres as
identified by hybridizing with a PNA-FISH probe (red). DNA was counterstained with DAPI (blue). Magnified views of merged images showing details
of the colocalization are shown in the two lower series of panels (B) Colocalized 53BP1 foci and PNA-FISH probe at telomeres was quantified. More
than 200 cells were analyzed in each cell line in an experiment performed three times with similar results. Asterisks indicate significant differences in
relation to different cell lines.
doi:10.1371/journal.pone.0101424.g003
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positive for the senescence SA-b-gal activity that increases to
almost 70% after bleomycin treatment. X-DC-1787-C cells
showed low expression of SA-b-gal that also increases further
after bleomycin treatment.
2- DNA damage is localized in telomeres in X-DC cells
Since telomere length is greatly diminished in X-DC patient
cells we investigated if DNA damage was enriched at telomeres,
both in basal conditions and after DNA damage induction. In
order to investigate this, we combined a PNA FISH probe as a
telomere marker, and 53BP1 for DNA damage detection. The
results showed that there was a high association of damaged DNA
Figure 4. F9A353V cells show enhanced, basal and bleomycin
induced, DNA damage response. (A) F9, F9A353V and F9A353V
cells transfected with GSE24.2 (10 mg DNA per million cells). F9A353V
24.2 cells were treated with bleomycin (10 mg/ml). After 0, 15 or 30
minutes of treatment cells were lysed and the experiment analyzed by
western blot with antibodies against c-H2A.X or a-tubulin as a loading
control. (B) Immunofluorescence staining of c-H2A.X (green) in F9,
F9A353V and F9A353V 24.2 cells (10 mg DNA per million cells). Nuclear
DNA was counterstained with DAPI (blue). (C) Quantification of c-H2AX
foci in F9, F9A353V or F9A353V 24.2 cells. More than 200 cells were
analyzed in each cell line and grouped to the number of c-H2A.X foci
observed per cell. Experiments were repeated 3 times with similar
results. Asterisks indicate significant differences in relation to different
cell lines.
doi:10.1371/journal.pone.0101424.g004
Figure 5. Localization of 53BP1 foci to telomeres in F9A353V
cells. F9, F9A353V and F9A353V cells transfected with GSE24.2
(F9A353V 24.2) (F9 cells were treated with bleomycin,10 mg/ml for 24
hours) and incubated with 53BP1 antibodies and with a PNA-FISH
probe. (A) Colocalization of 53BP1 foci (green) and PNA-FISH probe that
identified telomeres (PNA-Tel, red). DNA was counterstained with DAPI
(blue). Magnified views of merged images showing details of the
colocalization are shown in the lower panels. (B) Quantification of the
colocalization of 53BP1 foci and telomere signals shown in panel A.
More than 200 cells were analyzed in each cell line and grouped to the
number of 53BP1 foci associated to telomeres (PNA-Tel) per cell.
Experiments were repeated 3 times with similar results. Asterisks
indicate significant differences in relation to different cell lines.
doi:10.1371/journal.pone.0101424.g005
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at the telomeres in X-DC-1774-P cells that was not found in
carrier X-DC-1787-C cells (Fig. 3A). Furthermore the increase in
DNA damage observed after bleomycin treatment (Fig. 1B) was
strongly associated with telomeres in X-DC-1774-P cells in
contrast to X-DC-1787-C cells (Fig. 3) indicating the relevance
of telomere shortening in the response to DNA damage in X-DC
patient cells.
3-Expression of GSE24.2 impairs the induction of c-H2A.X
foci after DNA damage
Since F9 cells represent a good model system to study DNA
damage responses as previously demonstrated (29), we used them
in order to investigate if the expression of GSE24.2 could modify
the activation of the DNA damage response. Therefore, we
transfected F9A353V and control F9 cells [26] with the GSE24.2
expression plasmid and treated them either with bleomycin or
etoposide, a topoisomerase inhibitor known to induce DNA
double-stranded breaks. We found that, as expected, bleomycin
treatment induced c-H2A.X in both cell lines (Fig. 4A). However,
the basal level of c-H2A.X was much higher in F9A353V cells
than in F9 cells expressing the WT dyskerin, indicating that the
mutation renders the cells more susceptible to DNA damage. In
the presence of the GSE24.2 F9A353V, c-H2A.X decreased to
values very similar to those observed in F9 cells in both, basal and
bleomycin-induced levels. Similar results were obtained in
etoposide-treated cells (data not shown). We next investigated
the presence of c-H2A.X containing foci in basal conditions and
the results confirmed those obtained in the western blot studies
(Fig. 4B and 4C). Most F9 cells showed very few foci; the number
increased in F9A353V cells but was reduced at similar level to
those of F9 cells when the mutant cells were transfected with
GSE24.2. Altogether, the results indicated that the expression of
GSE24.2 decreases the DNA damage produced by the dyskerin
mutation.
Afterwards, we investigated if the increased DNA damage in
F9A353V cells was enriched at the telomeres (as already found in
X-DC patient cells, Fig. 3) and also whether the protection from
DNA damage induced by GSE24.2 also applies to damage at the
telomeres. We use combined immunological detection of 53BP1
and PNA-FISH probe. The results (Fig. 5A and 5B) indicated that
F9A353V cells have a stronger association of 53BP1 to the
telomeres than in F9 cells treated with bleomycin, up to 60%.
However in F9A353V cells transfected with the GSE24.2 there is
little association of 53BP1 foci at the telomeres (30% 1–3 53BP1
foci per cell). These results indicate that the elevated DNA damage
response found in F9A353V cells is probably caused by defects at
the telomeres induced by the Dkc1 mutation, in agreement with
the results obtained in Dkc1D15 MEF cells. Interestingly, expression
Figure 6. Activity of the GSE24.2 peptide expressed in bacteria or chemically-synthesized. (A) F9A353V cells were transfected with 15 mg
of b-galactosidase as a control (galactosidase), or GSE24.2 purified from E. Coli (GSE24.2E.coli) or obtained by chemical synthesis (GSE24.2 synthetic).
After 24 hours cells were lysed and the levels of c-H2AX and a-tubulin determined by western blot. The values at the bottom were obtained after
quantification of the blot and show the ration between expression levels of c-H2AX and a-tubulin in each line and referred to those found in b-
galactosidase transfected cells. (B) Same experiment described in A, performed in X-DC3 cells transfected with b-galactosidase or chemically
synthesized GSE24.2. (C) Reactivation of telomerase activity by chemically synthesized GSE24.2. X-DC3cells were transfected with b-galactosidase or
chemically synthesized GSE24.2 and telomerase activity determined by TRAP assay (right). Different amounts extract were used for each TRAP assay
as indicated. The activity was quantified by evaluating the intensity of the bands in relation with the internal control (TEL/IC) (left panel). The values
for GSE24.2 transfected cells were referred to the b-galactosidase transfected cells. The experiments were repeated at least three times with similar
results. Asterisks indicate significant differences between the two different transfected peptides.
doi:10.1371/journal.pone.0101424.g006
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of GSE24.2 reverted the telomere damage in F9A353V cells,
indicating its biological importance in the reversion of the mutant
Dkc1 phenotype.
4-Treatment of X-DC cells with GSE24.2 peptide rescues
DNA damage
We have previously reported that the GSE24.2 peptide purified
from bacteria was able to increase telomerase activity in F9A353V
cells [26] therefore we next tested if the activity of the GSE24.2
peptide either purified from E-coli or chemically synthesized
reduced the DNA damage. We found that the levels of c-H2A.X
in F9A353V cells decreased after transfecting this peptide (Fig. 6A)
either obtained from bacteria or chemically synthesized to 30 and
20%, respectively. Moreover the synthetic peptide also decreased
the DNA damage in X-DC3 cells (DKC1 mutated lymphocytes)
by 30% (Fig. 6B). This decrease in DNA damage correlated well
with the ability of the synthetic peptide to increase telomerase
activity in these cells (Fig. 6C).
5- Oxidative stress in X-DC cells is decreased by
expression of GSE24.2
Oxidative stress is one of the causes of DNA damage producing
both single-strand breaks (SSBs) and double-strand breaks (DSBs).
SSBs are the result from the interaction of hydroxyl radicals with
deoxyribose and subsequent generation of peroxyl-radicals. These
reactive oxygen species (ROS) are then responsible for nicking
phosphodiester bonds that form the backbone of each helical
strand of DNA [34]. To clarify the presence of higher oxidation
levels in X-DC cells we have studied ROS levels, and the
expression of antioxidant enzymes CuZn (SOD1) and Mn (SOD2)
superoxide dismutase, glutathione peroxidase 1 (GPX1) and their
corresponding enzymatic activities in X-DC-1787-C and X-DC-
1774-P cell lines. Levels of ROS were elevated in X-DC-1774-P
cells compared with X-DC-1787-C carrier cells and also higher
than in GM03348, an age-matched cell line from a healthy subject
(data not shown). In agreement with this result we found a
decrease in gene expression levels of the antioxidant enzymes
CuZnSOD and MnSOD and GPX1 when compared the X-DC-
1774-P to the carrier cell line (Fig. 7A). We also determined the
activity of the three enzymes with decreased expression in the X-
DC-1774-P cells that also showed decreased activity in agreement
with the gene expression data (Fig. 7B).
In order to investigate if expression of GSE24.2 was able to
overcome the increased oxidative stress found in X-DC-1774-P
cells, we expressed in this cell line either pLNCX-GSE24.2 or the
empty vector (pLNCX). The results indicated that X-DC-1774-P
cells expressing GSE24.2 showed lower levels of ROS. We also
studied the expression levels of CuZnSOD, MnSOD and catalase
in both cell lines and found that expression levels of these
antioxidant enzymes were higher in X-DC-1774-P-24.2. When
the corresponding protein activities were analyzed, we observed an
increase in CuZnSOD, MnSOD and catalase activities (Fig. 7C) in
X-DC-1774-P-24.2 when compared with the empty vector
transfected cells. Altogether, the data indicated that the observed
decrease in oxidative stress in X-DC cells expressing GSE24.2
should contribute to protect these cells from DNA damage. We
finally investigated if treatment with the GSE24.2 synthetic
peptide was also able to induce a decrease in oxidative DNA
damage. We transfected X-DC-1774-P cells with the GSE24.2
synthetic peptide and evaluated the levels of 8-oxoguanine by
immunofluorescence (Fig 7E). The results showed that indeed the
synthetic GSE24.4 reduced the signal obtained with 8-oxogua-
nine-antibody.
Discussion
We have previously reported that expression of a dyskerin
internal peptide (GSE24.2) reactivates telomerase activity in cells
that are deficient in this activity by increasing TERT and TERC
levels [24] We have also reported that expression of GSE24.2
increases TR levels by stabilizing this RNA [26]. Because of this
activity GSE24.2 has been recently approved as an orphan drug
by EMA for the treatment of Dyskeratosis congenita. We have
now studied the role of GSE24.2 in the DNA damage response of
X-DC patient cells in an effort to better understand the
mechanism of GSE24.2 action in X-DC. We studied several
proteins involved in the DNA-damage response and found, as
other authors have [35] [36], that X-DC patient cells presented
higher levels of DNA damage associated foci detected by c-H2A.X
and 53BP1 and to a lesser extent p-ATM and p-CHK2. We also
found increased levels of DNA damage in response to bleomycin
that was more evident when we studied -H2A.X, p-ATM and p-
CHK2 associated foci as previously described in mice (29) but this
increase was not higher than that obtained in control cells
probably because X-DC cells already have massive damage in
basal conditions. Previous reports described increased levels of
DNA damage in DC cells harboring mutations in DKC1, TERC or
TERT. However in fibroblasts and lymphocytes from these
patients the response to induced DNA-damage was not increased
[35] in contrast to another study [29]. We have here used X-DC
patient cells which exhibited short telomeres, p53 activation and
senescence [37]. Indeed, a high level of DNA damage, both at
basal and induced by bleomycin, was observed at telomeres
suggesting that the shortening of telomeres in these cells induces
further damage by preventing repair. Dysfunctional telomeres
trigger a DNA damage response most likely because they are too
short to adopt the normal t-loop structure needed to form the
telomere with correctly ordered shelterin components. Recruit-
ment of histone-macroH2A.1 has been associated to heterochro-
matin and senescent associated foci (SAHF) [18] [19]. We found
that both senescence and macroH2A.1 associated-foci are
increased in X-DC patient cells and also that bleomycin treatment
increases these values, suggesting that the impairment in the repair
of DNA lesions in X-DC cells likely contributes to the senescent
phenotype.
Using the in vitro generated Dkc1 mutant F9A353V cells we have
found, in agreement with our previous results (and also [29]), that
Figure 7. Oxidative stress analysis in X-DC fibroblasts after GSE24.2 transfection. (A) ROS levels were determined in fibroblasts from the
carrier DC1787, and fibroblasts from the patient X-DC1774-P. Levels were determined using the fluorescent probe dihydroethidium in confluent cells
(left panel). RNA expression was determined for CuZnSOD, MnSOD, and GPX1 by qRT-PCR (A right panels). B) Enzymatic activities of
CuZnSOD,MnSOD, and Glutathione peroxidase 1 were also determined. C) ROS levels were studied in X-DC1774-P fibroblasts (expressing pLNCX
vector) and X-DC-1774-P cells expressing GSE24.2 (X-DC1774-PGSE24.2, left panel). Cu/ZnSOD, MnSOD, and catalase expression levels were
determined by qRT-PCR. D) Cu/ZnSOD, MnSOD, and catalase activities in confluent pLNCX and 24.2 cells are shown in left panels. E) X-DC1774-P and
X-DC1774-PGSE24.2, cells were transfected with GSE24.2 synthetic peptide and levels of 8-oxoguanine studied by immunofluorescence. The 8-
oxoguanine foci signal was expressed as the average number of foci/cell in 200 cells. Results are expressed as mean 6 standard deviation from three
independent experiments. Statistical significance is expressed as (*) p,0.05.
doi:10.1371/journal.pone.0101424.g007
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these cells showed increased DDR compared with F9 cells, both in
the steady state and when treated with bleomycin or etoposide.
Other Dkc1 mutations such as Dkc1D15 have been shown to
accumulate DNA damage indicating that DC cells have cellular
defects even in the context of long telomeres [29]. We previously
reported that an internal fragment of Dyskerin, the peptide
GSE24.2 induces an increase in telomerase activity in X-DC cells
[24]. Now we are showing that expression of GSE24.2 is able to
induce protection against DNA damage. Furthermore, the repair
of pre-existing DNA lesions should also take place at telomeres in
F9A353V cells as shown by the decrease in 53BP1 and PNA-FISH
telomeric colocalization (Fig. 5B). Interestingly, the observed
decrease in DNA damage mediated by GSE24.2 expression in
F9A353V cells, also occurs when we used either bacterially
produced or chemically synthesized peptide, reinforcing the idea
that GSE24.2 reactivates telomerase activity, by acting directly at
the telomeric DNA [26] and/or changing telomere folding.
According with these results the transfection of the GSE24.2
synthetic peptide into X-DC3 human patient lymphocytes resulted
in both increased telomerase activity and decreased DNA damage.
On the other hand the consequences of A353V-X-DC mutation
on DNA damage resemble to those found in cells with mutations
in Tin2 and Pot1, which are structural components of telomeres
[38] [39].
Diseases with telomerase deficiency are linked to oxidative
stress. Elevated levels of the lipoperoxide malondialdehide (MDA)
[40], and MDA-DNA adducts have been reported in rare
degenerative diseases [41] and in aging [42]. In addition, oxidative
stress conditions caused by H2O2 increased the rate of telomere
shortening in fibroblasts from ataxia-telangiectasia patients [43].
Furthermore, increased accumulation of ROS is involved in
decreased cell growth in a DKCD15 mouse model [36], though
there is very little information about oxidative stress in human X-
DC cells. Interestingly, the existence of oxidative stress in
lymphocytes from patients with an autosomal dominant form of
DC with mutations in TERC has been recently reported [44]. To
further increase the characterization of the oxidative stress profile
in X-DC we characterize the levels of ROS and the expression
and activity of the main antioxidant enzymes. We found in X-DC-
1774-P an increase in ROS levels and a decrease in the expression
and activity of antioxidant enzymes in patient cells when
compared to carrier cells. Interestingly expression of GSE24.2
results in an increase in SOD1, SOD2 and catalase expression that
might decrease ROS levels in X-DC-1774-P 24.2 cells. Different
groups [45] [46] [47] [48] have reported decreased cellular ROS
levels in stressed hTERT over-expressing cells, demonstrating that
telomerase re-expression contributes to decrease oxidative stress
[49]. The work by Westin et al. demonstrated that the reduction of
the levels of superoxide in DC cells was not dependent of the
localization of TERT in the mitochondria, but also p53/p21WAF/CIP-
dependent process in the context of telomere shortening in cells from
DC patients. Therefore, our findings reinforce the notion that
increased telomerase activity [24] and repair of DNA damage at
telomeres induced by GSE24.2 is concomitant with a decrease
in oxidative stress in X-DC cells. Alternatively the decreased
DNA damage detected by c-H2A.X, might corresponds to
decreased oxidative damage, in agreement of our results
evaluating the levels of 8-oxoguanine that decreased after
transfection of the GSE24.2 synthetic peptide.
In summary our results show that, GSE24.2 attenuates the
impact of the DKC1 mutations on DNA damage and its incidence
on telomeres (Fig. 8). Furthermore, oxidative stress decreases in
GSE24.2 expressing cells, and this should contribute to decrease
the rate of DNA damage and therefore enable restoration of cell
cycle progression. Indeed, we have previously shown that
expression of GSE24.2 X-DC fibroblasts restores proliferation
[26].
Since GSE24.2 has been approved as an orphan drug for the
treatment of DC, the results presented here indicate that
expression of GSE24.2 may form the basis of a useful and safe
therapeutic strategy for X-DC patients either by using it as a
permanent or as a temporal telomerase activator. These results
indicate that GSE24.2 expression has a broad effect on DC cells,
reducing oxidative stress and DNA damage in addition to
reactivating telomerase activity. All these protective effects could
cooperatively contribute to increase DC cells survival and
Figure 8. Proposed biological activity of GSE24.2 on DNA damage and oxidative stress. Dyskeratosis congenita cells display high basal
DNA damage detected by increased cH2AX, p-ATM, p-CHK2 and 53BP1 foci. Additionally there are increased levels of ROS, and decreased expression
and activity of antioxidant enzymes resulting in higher oxidative damage and senescence (left panel). GSE24.2 peptide increases expression of
antioxidant enzymes and as a consequence decreased ROS levels (right panel). In parallel there is increased telomerase activity that may help to
decrease global and telomeric DNA damage. Globally these two activities of GSE24.2 might result in increased viability and growth of DC cells (26).
doi:10.1371/journal.pone.0101424.g008
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proliferation [26] and give further support to the recent approval
of GSE24.2 as an orphan drug for DC treatment.
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